Cannabis Science Expands Clinical Studies to Include Selected Patients for Asthma, Several Important Pain Targets, and Sleep Deprivation With Additional Medications

IRVINE, CA--(Marketwired - Sep 13, 2016) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce that thus far more than 100 individuals have expressed interest in participating in the initial round of trials for Cannabis Science's new inhalation study for asthma/COPD and other respiratory conditions. The company has been thoroughly impressed with the interest in their alternative treatment.

Due to the large demand, Cannabis Science has received several new products that the company is expanding into its clinical studies on a state-by-state basis beginning in the State of California. These new products are designed to target asthma, severe pain management, and sleep disorders.

Twenty five (25) legal, self-medicating patients in California are currently being selected for our initial asthma/COPD inhalation medicine study. Fortunately, we will expand this study and will seek out new applicants in the state of California. Sufferers of aching muscles and joints, headaches, and menstrual cramps are encouraged to apply to test the company's new "Natural Body & Soul Healing Balm."

Self-medicating patients with coughs, colds, and/or strains of the flu are encouraged to seek relief by participating in the company's new "Relief Tonic" trial, which aims to bolster the body's natural immune system by infusing cannabis extract oil with a variety of other all-natural ingredients.

Finally, self-medicating patients suffering from sleep deprivation or other sleep disorders may be interested in participating in testing the company's "Solace Drops," which are being tested as a natural sleep aid that seeks to avoid the habit-forming nature of many less natural sleeping treatments.

The company will begin contacting the chosen individuals to begin trials in the near future. Applicants for additional new treatments are being sought out, and shareholders are encouraged to apply for these initial test studies. These new clinical studies will accept 50 patients each, the company hopes to streamline the clinical studies process to bring the medication to more patients with a full-scale launch soon.

"We are so grateful to have so many willing self-medicating patients to help us in these trials of our new products. We already have labels made and are ready to move forward with commercializing our new medications, and looking forward to successful clinical studies so we can move on to the next level," said CEO Raymond C. Dabney. "While there is a great deal of research backing using cannabis in pain treatments, respiratory system treatments, and as a sleep aid, we are putting our products through serious studies to improve upon them before a wider spread release."

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.